Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1131Triple Negative Breast Neoplasms 147Neoplasm Metastasis 99Carcinoma, Non-Small-Cell Lung 85Ovarian Neoplasms 81Neoplasms 75Lung Neoplasms 64Colorectal Neoplasms 60Melanoma 59Stomach Neoplasms 44Pancreatic Neoplasms 43Breast Neoplasms, Male 43Prostatic Neoplasms 42Carcinoma, Renal Cell 37Squamous Cell Carcinoma of Head and Neck 34Sarcoma 30Colonic Neoplasms 29Endometrial Neoplasms 28Head and Neck Neoplasms 26Brain Neoplasms 24Urinary Bladder Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 21Carcinoma, Intraductal, Noninfiltrating 21Lymphoma, Non-Hodgkin 19Recurrence 18Uterine Cervical Neoplasms 17Inflammatory Breast Neoplasms 17Breast Carcinoma In Situ 17Multiple Myeloma 16

Interventions

exemestane 1Paclitaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × First Line Metastatic Breast Cancer × Breast × Clear all
NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

ARCAGY/ GINECO GROUP

Phase 3 Terminated
117 enrolled
Breast

First Line Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡